Assembly Biosciences Z Score

Key Indicators . Z Score . Stocks . USA . 
Stock . Assembly Biosciences
ASMB Stock  USD 29.74  -1.19  -3.85%   

The Altman Z-Score combines liquidity, profitability, leverage, and efficiency ratios into one standardized financial health measure. Assembly Biosciences operates outside the asset-intensive profile the Z-Score was calibrated against, so readings should be contextualized with margin, cash flow, and sector-specific health measures.

Assembly Biosciences Z-Score Ranges

Above 3.0: stronger financial condition range
2.7-3.0: transition range
1.8-2.7: watch range
Below 1.8: higher distress probability range

Why Z-Score Matters for Assembly Biosciences

The score was originally calibrated against firms that subsequently filed for bankruptcy, giving it empirical grounding as a distress predictor. For screening purposes, it flags companies where liquidity, leverage, and earnings power are deteriorating simultaneously rather than in isolation.

Related Analysis

Piotroski F Score | Valuation | Assembly Biosciences Financial Statements | Forecast | Competitors
Additional detail on trading Assembly Stock is available in our How to Trade Assembly Stock guide.
  

Assembly Biosciences' Z-Score is a linear multi-factor model designed to assess financial distress risk using a weighted combination of accounting ratios. Its interpretation depends on industry context and may be less directly comparable for asset-light business models. The model uses five fundamental business ratios that are weighted according to the algorithm of Professor Edward Altman who developed it in the late 1960s at New York University.

Z Score

 = 

Sum Of

5 Factors

ComponentValueWeightWeighted
Working Capital / Total Assets205.77 million / 257.59 million1.20.96
Retained Earnings / Total Assets-832.05 million / 257.59 million1.4-4.52
EBITDA / Total Assets-11.99 million / 257.59 million3.3-0.15
Market Cap / Total Debt472.65 million / 2.63 million0.6107.91
Revenue / Total Assets
72.3 million / 257.59 million0.9990.28
Z-Score
104.47
Note: Altman's original specification uses EBIT for the third factor. Using EBITDA instead of EBIT may overstate T3, potentially inflating the overall Z-Score relative to the original specification.

Z Score Driver Correlations

The correlation structure highlights how Z Score relates to Assembly Biosciences' primary financial indicators. Strong positive values indicate co-directional movement; negative values indicate inverse relationships.
Click cells to compare fundamentals
Competition

Assembly Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

-43,050
Accumulated Other Comprehensive Income stood at $-41,000 as of December 31, 2025.

Fundamental Drivers Relationships

Institutional Holders

Institutional ownership in Assembly Biosciences comprises shares held by pension funds, endowments, and investment managers. Institutions may hold large blocks of Assembly Biosciences' outstanding shares and exert considerable management influence.
Shares
B Group, Inc2025-12-31
175.7 K
Adage Capital Partners Gp Llc2025-12-31
161 K
Eversept Partners, Lp2025-12-31
159.7 K
Stempoint Capital Lp2025-12-31
156.7 K
Geode Capital Management, Llc2025-12-31
131.3 K
Marshall Wace Asset Management Ltd2025-12-31
129.1 K
Patient Square Capital Lp2025-12-31
127 K
Caption Management, Llc2025-12-31
106.6 K
Millennium Management Llc2025-12-31
98.2 K
Farallon Capital Management, L.l.c.2025-12-31
1.2 M
Ra Capital Management, Llc2025-12-31
1 M

Important Fundamentals

Return On Equity TTM-0.0566
Return On Asset TTM-0.0506
Profit Margin TTM-0.0898
Operating Margin TTM-1.38
Current Valuation198.56 M
Shares Outstanding15.89 M
Shares Owned By Insiders32.37 %
Shares Owned By Institutions60.08 %
Number Of Shares Shorted1.53 M
Price To Earnings TTM-10.58 X
Price To Book TTM2.15 X
Price To Sales TTM6.65 X
Revenue TTM72.3 M
Gross Profit TTM6.28 M
EBITDA TTM-11.99 M
Net Income TTM-6.12 M
Cash And Equivalents TTM116.69 M
Cash Per Share TTM2.41 X
Total Debt TTM2.63 M
Debt To Equity TTM0.04 %
Current Ratio TTM8.31 X
Book Value Per Share TTM13.04 X
Cash Flow From Operations TTM-41.09 M
Short Ratio TTM18.86 X
Earnings Per Share0.08 X
Target Price48.75
Number Of Employees73
Trailing Beta1.09
Market Capitalization TTM472.65 M
Total Asset TTM257.59 M
Retained Earnings TTM-832.05 M
Working Capital TTM205.77 M
Current Asset TTM68.37 M
Current Liabilities TTM3.4 M
Net Asset257.59 M

Altman Z-Score Methodology & Financial Data

Altman's discriminant model is applied to Assembly Biosciences using five balance-sheet and income-statement inputs. The five ratios are weighted differently in the formula, with EBIT-to-Assets and Market-to-Liabilities carrying the largest coefficients. Assembly Biosciences currently reports current ratio of 8.31, debt-to-equity of 0.04, working capital of 205.77 million.

Assembly Biosciences analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Analyst inputs may be included when coverage is available.

Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.